Pharmaceutical Research and Manufacturers of America (PhRMA) have announced the recipients of PhRMA's 2008 Discoverers Award and the 2008 Clinical Trial Exceptional Service Award.
PhRMA presented its highest award, The Clinical Trial Exceptional Service Award, to researchers and biopharmaceutical company scientists who helped discover GlaxoSmithKline's (NYSE:GSK) cardiovascular medicine Coreg.
Coreg has reduced the number of deaths of patients with congestive heart failure and to treat hypertension and reduce recurrent heart attacks.
The Discoverers Award was presented to three scientists from SmithKline Beecham who discovered the prescription drug Coreg. The recipients of the award are Eliot Ohlstein, Ph.D., Senior Vice President and head of the Cardiovascular &
Urogenital Diseases Center of Excellence for Drug Discovery at GSK; Robert Ruffolo, Jr., Ph.D., formerly an R&D executive at the GSK heritage company and now President, Research & Development at Wyeth; and Tian-Li Yue, Ph.D., Manager, Department of Investigative & Cardiac Biology, Cardiovascular Urogenital Centre of Excellence in Drug Discovery at GSK.
Alan Metz, M.D., GlaxoSmithKline's Vice President and Medical Director, North America, stated that, "Coreg is a wonderful example of how creative science can change the fundamental thinking about the way we treat disease, and how innovation can make a life-saving difference to patients. The scientists we honor today championed this achievement, and hundreds of others in GSK shared their vision and passion to make this medicine a reality. This award honors all of them."
The Clinical Trial Exceptional Service Award was also presented to Lucy Angioletti. Angioletti was a patient who participated in the Coreg clinical trials.
[Source: PhRMA]
.jpg)
Comment Preview